Corporate Symposia
*Lunch will be provided to the session attendees (marked with* below)
Friday, October 18, 2024
Corporate Symposium (CS01) | Servier*
Multidisciplinary clinical management of diffuse glioma patients: Is it still the era of watch & wait?
Friday, October 18, 13:30 - 14:30 hrs, M1
| 13:30 – 13:40 | Welcome & Introduction Welcome; Essentials on diffuse glioma management; Overview of the program |
Matthias Preusser, Austria | |
| 13:40 – 13:50 | The Neurosurgeon Perspective: Why and how going beyond surgery? |
Joerg Tonn, Germany | |
| 13:50 – 14:00 | The Psychologist Perspective: How much quality-of-life matters, and can we achieve shared-decision making?. |
Florien Boele, United Kingdom | |
| 14:00 – 14:10 | The Patient Perspective: How can we express our considerations and develop our abilities to act empowerment? |
Tba Tba, Tba | |
| 14:10 – 14:25 | Panel Discussion/Q&A |
| All Faculty members | |
| 14:25 – 14:30 | Conclusion James Perry, Canada |
Corporate Symposium (CS02) | Novocure* (not intended for US healthcare professionals)
Real World Evidence: 10 Years of Experience Treating High Grade Glioma with Tumor Treating Fields (TTFields) Therapy
Friday, October 18, 13:30- 14:30 hrs, Alsh
| 13:30 – 13:35 | Welcome & Introduction |
Luis Castelo-Branco, Switzerland | |
| 13:35 – 13:45 | Relevance of Real-World Evidence (RWE) |
Luis Castelo-Branco, Switzerland | |
| 13:45 – 13:55 | Introduction to TTFields & RWE Data |
Matthew Williams, United Kingdom | |
| 13:55 – 14:10 | The TIGER Experience |
| Oliver Bär, Germany | |
| 14:10 – 14:20 | Importance of RWE from a Regulatory Perspective |
| Luis Castelo-Branco, Switzerland | |
| 14:20 – 14:30 | Closing and Q&A |
| All | |
Saturday, October 19, 2024
Corporate Symposium (CS03) | Imvax
Development of IGV-001 for the treatment of newly diagnosed glioblastoma
Saturday, October 19, 13:00 - 14:00 hrs, M1
| 13:00 – 13:05 | Welcome and introductions |
Raul Perez-Olle, United States | |
| 13:05 – 13:15 | Imvax overview. The GoldspireTM platform. |
Raul Perez-Olle, United States | |
| 13:15 – 13:30 | Early development of IGV-001 in glioblastomaTreatment Landscape |
Soma Sengupta, United States | |
| 13:30 – 13:50 |
Phase 2b study of IGV-001 in newly diagnosed glioblastoma |
Simon Hanft, United States | |
| 13:50 – 14:00 | Q&A |
Corporate Symposium (CS04) | Medtronic
LITT* as a surgical minimally invasive treatment option in neuro-oncology
(*Laser Interstitial Thermal Therapy)
Saturday, October 19, 13:00 - 13:30 hrs, Alsh
Chairs: Jiri Bartek, Margret Jensdottir
| 13:00 – 13:15 | Basic overview of LITT procedure for treating brain tumours, patient selection and literature overview |
| Jiri Bartek, Sweden | |
| 13:15 – 13:25 | Clinical experience with LITT and case presentation |
Margret Jensdottir, Sweden | |
| 13:25 – 13:30 | Questions & Answers |
